Phase I Trial of Durvalumab and Olaparib with Radiation for Unresectable Pancreatic Cancer
A phase I trial is underway to evaluate the safety and tolerability of olaparib combined with durvalumab and radiation therapy in patients with locally advanced unresectable pancreatic cancer.
Phase I
National Cancer Institute
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing phase I trial of durvalumab and olaparib combined with radiation therapy represents a significant advancement in the treatment of locally advanced unresectable pancreatic cancer. Success in this trial could reshape treatment protocols and enhance competitive positioning for companies involved in PARP inhibitors and immunotherapies.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results for safety and efficacy, as well as subsequent developments in combination therapy approaches for pancreatic cancer.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.